Peter Greenleaf
Equibles does not estimate personal net worth.
About Peter Greenleaf
Peter Greenleaf is recorded as CEO at Avalo Therapeutics, Inc. (AVTX). The proxy statement of Avalo Therapeutics, Inc. reports total compensation of $735,204 for Peter Greenleaf in fiscal 2019, including a base salary of $175,750. Disclosed compensation is on record for 2 fiscal years. Avalo Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Avalo Therapeutics, Inc. includes Garry A. Neil (CEO), Garry Neil (CEO and Board Member), Michael Cola (CEO, Chairman and Board Member) and 7 others.
Affiliation history
-
Current
Company network
Leadership on record at Avalo Therapeutics, Inc.
- Garry A. Neil CEO
- Garry Neil CEO, Board Member
- Michael Cola CEO, Chairman, Board Member
- Michael F. Cola CEO, Board Member
- Michael Heffernan Chairman, Board Member
- Sol Barer Chairman, Board Member
- Sol J. Barer Chairman, Board Member
- Chris Sullivan CFO
- Christopher Sullivan CFO, Chief Accounting Officer
- Schond L. Greenway CFO
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2019 | Avalo Therapeutics, Inc. (AVTX) | Former Chief Executive Officer and former Principal Executive Officer | $175,750 | $735,204 |
| 2018 | Avalo Therapeutics, Inc. (AVTX) | Former Chief Executive Officer and former Principal Executive Officer | $456,000 | $5,090,787 |
Recent activity
No call appearances or filed executive changes recorded yet.